Yoshihiko Tasaki, Yosuke Sugiyama, Shuzo Hamamoto, Taku Naiki, Takehiro Uemura, Keisuke Yokota, Daisuke Kawakita, Motoki Nakamura, Ryo Ogawa, Takaya Shimura, Yoshihisa Mimura, Yuji Hotta, Kunihiro Odagiri, Nanami Ito, Moeko Iida, Yuka Kimura, Hirokazu Komatsu, Hiromi Kataoka, Shuji Takiguchi, Akimichi Morita, Shinichi Iwasaki, Katsuhiro Okuda, Akio Niimi, Takahiro Yasui, Yoko Furukawa-Hibi
BACKGROUND: Immune checkpoint inhibitors (ICIs) can cause severe immune-related adverse events (irAEs). However, biomarkers for irAEs common to different types of ICIs and cancers have not been reported. This study examined whether eosinophils can be used as a predictor of irAEs. METHODS: Six hundred fourteen patients with cancer (esophageal, gastric, head and neck, lung, melanoma, renal cell, urothelial, and other cancer) received anti-PD-1, anti-PD-L1, or anti-CTLA-4 plus anti-PD-1 therapy...
November 21, 2023: Cancer Medicine